Top image

Member Experiences in an Australian Translational Cancer Research Cenre

RESEARCH TYPE
T1,T2,T3
PROGRAM
Sydney Catalyst Supported
TAGS
    Member Experience
STATUS
Complete

The experience of membership of multidisciplinary translational research collaborations (TRCs) is largely unreported. Sydney Catalyst Translational Cancer Research Centre is a multidisciplinary consortium of researchers and clinicians from institutions in metropolitan Sydney and regional New South Wales, Australia. This study aimed to qualitatively explore the experience of being a member of Sydney Catalyst and to identify members' understanding of translational research and perceptions of the benefits of membership of a TRC.

Download the full publication here

You might also be interested in...

  • Cancer multidisciplinary team meetings in practice
    A new Sydney Catalyst led article has recently been published:  "Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantative survey and implications for...
  • Consumer Engagement in Cancer Research
    Consumers are people who have been affected by cancer - patients, survivors, carers, or close family members or friends of someone diagnosed with cancer or in some circumstances, members of the ge...
  • Development of a Web Portal for Physical Activity and Symptom Tracking in Oncology Patients
    Development of a Web Portal for Physical Activity and Symptom Tracking in Oncology Patients: Protocol for a Prospective Cohort Study Background: Significant benefits accrue from increasing physi...
  • in situ decellularization of tissues for high-resolution imaging
    Summary The extracellular matrix (ECM) is a master regulator of cellular phenotype and behavior. It has a crucial role in both normal tissue homeostasis and disease pathology. Here we present a f...
  • In vivo photolabeling of tumor-infiltrating cells
    Summary Understanding the consequences of immune infiltration of solid tumors is vital to continued development of successful immune therapies. However, little is known about the fate of tumor-ex...
  • Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
    Summary The results of this first-in-man study of TargomiRs showed that a dose of 5 × 10⁹ TargomiRs per week was well tolerated and was accompanied by early signs of antitumour activity. This stu...
  • Writing Successful Grants for Translational Research
    We've created this Prezi presentation for anyone wanting to write successful grants for translational research. The information contained within is based on the experiences and advice f...